secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001193125-24-274327
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma terminates $150M ATM equity offering program
----------------------------------------------------------------

- Company delivered notice to Cowen and TD Cowen to suspend and terminate ATM prospectus supplement dated August 9, 2024.
- Program allowed for sale of up to $150M of ordinary shares.
- No sales will be made under Sales Agreement until new prospectus or registration statement is filed.
- Sales Agreement remains in full force and effect other than the terminated ATM prospectus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524274327/0001193125-24-274327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524274327/d913585d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-274327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer